

## LU CODES

LU Code	Description	Period
132	For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Note: this drug is not for relief of acute symptoms	Indefinite
256	Patients who have a tracheostomy	Indefinite
257	Patients with cystic fibrosis in whom nebulizer therapy is indicated	Indefinite
258	Patients with severe mental or physical disabilities	Indefinite
259	Patients who have previously used nebulizer therapy within the last 12 month period	Indefinite
265	Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy	Indefinite
266	Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated	Indefinite
267	Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities	Indefinite
268	Patients who have previously used nebulizer therapy within the last 12 month period	Indefinite
330	For treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms	Indefinite
391	For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic	Indefinite
394	For patients with uncomplicated urinary tract infections (acute cystitis) who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as general benefits	1 year
443	For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic	Indefinite
456	For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e. LABA or LAMA). Notes: COPD disease severity is based on spirometry, symptoms, and disability	Indefinite
459	For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e. LABA or LAMA). Notes: COPD disease severity is based on spirometry, symptoms, and disability	Indefinite
533	For patients who are unable to swallow or tolerate solid oral dosage forms	1 year

549	For the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infections	1 year
567	For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis, and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA)	Indefinite

**REFERENCES:**

Prescribe Smart: the Modern Drug Formulary. 2019. Accessed from: <https://www.prescribessmart.com/>. Accessed on 25-Mar-2022.